BlackRock Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

BlackRock Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.74M	Sell	71,427 -116,125	-62%	-$3.31M	﹤0.01%	1582
2016 Q3	$7.11M	Sell	187,552 -3,811	-2%	-$120K	0.01%	1008
2016 Q2	$5.7M	Buy	191,363 +3,717	+2%	+$131K	0.01%	1055
2016 Q1	$5.55M	Buy	187,646 +21,525	+13%	+$646K	0.01%	1061
2015 Q4	$7.53M	Sell	166,121 -152	-0.1%	-$6.62K	0.01%	964
2015 Q3	$6.25M	Buy	+166,273	New	+$7.63M	0.01%	1007

Other funds holding RCKT

RCP

Rho Capital Partners New York $20.4M AUM

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BlackRock Advisors's RCKT Position: Q4 2016 in Review

BlackRock Advisors reduced its Rocket Pharmaceuticals (RCKT) stake by 62% in Q4 2016, selling an estimated $3.31M and leaving 71,427 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1582.

BlackRock Advisors first reported a position in RCKT in Q3 2015 and has held it in 6 quarters since. The position peaked at $7.53M in Q4 2015. 82 funds tracked by Wall St. Rank hold RCKT as of Q4 2016.

BlackRock Advisors held 71,427 shares of Rocket Pharmaceuticals worth $1.74M as of Q4 2016.
BlackRock Advisors sold 116,125 Rocket Pharmaceuticals shares in Q4 2016, an estimated $3.31M.
Rocket Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1582 holding.
BlackRock Advisors first reported a position in Rocket Pharmaceuticals in Q3 2015 and has held it in 6 quarters since.
BlackRock Advisors's Rocket Pharmaceuticals position peaked at $7.53M in Q4 2015.
82 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.